Home Cart Sign in  
Chemical Structure| 39809-25-1 Chemical Structure| 39809-25-1

Structure of Penciclovir
CAS No.: 39809-25-1

Chemical Structure| 39809-25-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Penciclovir is a guanosine analogue antiviral drug as a DNA polymerase inhibitor.

Synonyms: BRL 39123; VSA 671

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Penciclovir

CAS No. :39809-25-1
Formula : C10H15N5O3
M.W : 253.26
SMILES Code : O=C1NC(N)=NC2=C1N=CN2CCC(CO)CO
Synonyms :
BRL 39123; VSA 671
MDL No. :MFCD00866931
InChI Key :JNTOCHDNEULJHD-UHFFFAOYSA-N
Pubchem ID :135398748

Safety of Penciclovir

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
C6 rat glioma cells 3 mCi/ml 15, 30, 60, 120, 240 minutes To determine the effects of coelenterazine dose on light yield, showing an approximately linear relationship between 0.1–10 µg/ml and peak signal at 50 µg/ml. PMC16007
C6 rat glioma cells 1.0 mCi/ml 15, 30, 60, 120, 240 minutes To determine the effects of coelenterazine dose on light yield, showing an approximately linear relationship between 0.1–10 µg/ml and peak signal at 50 µg/ml. PMC16007
U87 cells 3.7 kBq/mL 30, 60, 120 minutes To assess the accumulation of penciclovir in transduced cells, results showed no accumulation of penciclovir in transduced cells PMC4405132

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Athymic nude mice U87MG and MDA-MB-435 tumor models Tail vein injection 1.25 × 10^12 v.p./kg Single injection, imaging performed 48 hours later Evaluate the transduction efficiency and targeting of RGD-PEG-modified adenovirus in vivo. RGD-PEG-Adtk showed significantly higher accumulation in tumors than in the liver, demonstrating good targeting. PMC4154793
Mice Experimental autoimmune encephalomyelitis (EAE) Intraperitoneal injection 25 or 100 mg/kg Daily starting from day 7 post-immunization To evaluate the therapeutic effect of penciclovir on EAE, results showed that penciclovir significantly reduced the incidence and severity of EAE and decreased T cell infiltration in the central nervous system. PMC3920559

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01832974 Adrenocortical Carcinoma Phase 1 Terminated(Business decision b... More >>y the sponsor during Phase 1.) Less << - United States, Maryland ... More >> National Cancer Institute at the National Institutes of Health Bethesda, Maryland, United States, 20892 Less <<
NCT02696811 DNA Damage In... More >>flammation Less << Not Applicable Completed - United Kingdom ... More >> Agriculture Building, Newcastle University Newcastle upon Tyne, Tyne and Wear, United Kingdom, NE1 7RU Less <<
NCT02423668 - Completed - -
NCT00866502 Parkinson's Disease Phase 1 Phase 2 Completed - Sweden ... More >> Lund University Hospital Lund, Sweden, 22185 Karolinska University Hospital, Huddinge Stockholm, Sweden, 141 86 Less <<
NCT00878072 Herpes Labialis Phase 2 Phase 3 Completed - United States, California ... More >> Women's Health Care at Frost Street San Diego, California, United States United States, Illinois Children's Memorial Hospital Chicago, Illinois, United States, 60614 United States, Indiana Medisphere Medical Research Center, LLC Evansville, Indiana, United States, 47714 United States, Missouri Clayton Medical Research St. Louis, Missouri, United States, 63117 United States, New York Rochester Clinical Research, Inc. Rochester, New York, United States United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 University Hospitals Case Medical Center Cleveland, Ohio, United States, 44106 United States, Oregon Westover Heights Clinic Portland, Oregon, United States, 97210 United States, Pennsylvania Primary Physicians Research, Inc Pittsburgh, Pennsylvania, United States United States, Texas Texas Children's Hospital Houston, Texas, United States, 77030 R/D Clinical Research, Inc Lake Jackson, Texas, United States, 77566 R/D Clinical Research Lake Jackson, Texas, United States, 77566 Less <<
NCT02592915 Intraoperative Neurophysiologi... More >>cal Monitoring Pain Management Less << Phase 3 Recruiting January 2021 Belgium ... More >> Queen Fabiola Children's University Hospital Recruiting Brussels, Belgium, 1020 Contact: Bernard Wenderickx, Mr    0032 2 477 36 54    bernard.wenderickx@huderf.be    Contact: Paul Mourlhou, Mr    0032 2 477 38 85    paul.mourlhou@huderf.be    Principal Investigator: Francoise De Pooter, MD          Sub-Investigator: Philippe Van der Linden, PhD          Sub-Investigator: Paul Deltenre, PhD Less <<
NCT02393027 Idiopathic Parkinson Disease Early Phase 1 Terminated(Enough inclusions f... More >>or interpretation) Less << - France ... More >> University Hospital Tours, France, 37044 Less <<
NCT02270879 - Completed - -
NCT00098059 - Completed - -
NCT00098059 Herpes Simplex Phase 3 Completed - United States, Alabama ... More >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35233-1711 United States, Colorado The Children's Hospital Denver, Colorado, United States, 80218 United States, Illinois Children's Memorial Hospital Chicago, Illinois, United States, 60614 United States, Kentucky Kosair Charities Pediatric Clinical Research Unit Louisville, Kentucky, United States, 40202-3830 United States, New York Columbia University Medical Center New York, New York, United States, 10032 State University of New York at Stony Brook, New York, United States, 11794-3362 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229-3039 University Hospitals of Cleveland Cleveland, Ohio, United States, 44106 United States, Texas Children's Medical Center of Dallas Dallas, Texas, United States, 75235 Baylor College of Medicine/Texas Children's Hospital Houston, Texas, United States, 77030 Panama Panama Minister of Health Ciudad de David, Chiriqui, Panama Panama Minister of Health Ciudad de Panama, Panama Less <<
NCT02038608 Parkinson's Disease Not Applicable Completed - France ... More >> Hospices Civils de Lyon, Hopital Neurologique Pierre Wertheimer Bron, France, 69500 Less <<
NCT02319382 Parkinson's Disease With LRRK2... More >> Mutation Healthy Controls Parkinson's Disease Without LRRK2 Mutation Less << Not Applicable Unknown December 2016 France ... More >> Orsay Hospital Recruiting Orsay, France, 91401 Contact: Philippe REMY, MD PhD    (0)1.69.86.77.27 ext +33    neuro-philippe.remy@hmn.aphp.fr    Contact: Sonia LAVISSE, PhD    (0)1.69.86.78.91 ext +33    sonia.lavisse@cea.fr Less <<
NCT02056496 Healthy Phase 1 Completed - Spain ... More >> UCAM (San Antonio Catholic University from Murcia) Murcia, Spain, 30107 Less <<
NCT03512171 Healthy Adults Phase 3 Completed - United States, Tennessee ... More >> Zald Affective Neuroscience Lab- Vanderbilt University Nashville, Tennessee, United States, 37203 Less <<
NCT01153802 Depressive Disorder Phase 1 Completed - United Kingdom ... More >> GSK Investigational Site Harrow, Middlesex, United Kingdom, HA1 3UJ Less <<
NCT01257074 Herpes Labialis Phase 3 Completed - Brazil ... More >> Flavia Addor São Paulo, Brazil Less <<
NCT01441778 Allergic Rhinitis Phase 2 Completed - Thailand ... More >> Araya Satdabudha Klong luang, Pratumthanee, Thailand, 12120 Less <<
NCT00820534 Cold Sore Phase 4 Completed - United Kingdom ... More >> Belfast Health and Social Care Trust, Royal Victoria Hospital Belfast, United Kingdom, BT12 6BA Less <<
NCT03675282 Parkinson Disease ... More >> REM Sleep Behavior Disorder Healthy Less << Phase 1 Phase 2 Recruiting January 31, 2021 United States, New York ... More >> Weill Cornell Medicine Recruiting New York, New York, United States, 10065 Contact: Eileen Chang    212-746-6248    eic2002@med.cornell.edu    Contact: Jamie Stern    (212) 746-9748       Principal Investigator: Alexander Shtilbans, MD Less <<
NCT00820534 - Completed - -
NCT03661541 HSV Herpes La... More >>bialis Less << Phase 1 Completed - United States, Minnesota ... More >> Prism Clinical Research, LLC Saint Paul, Minnesota, United States, 55114 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.95mL

0.79mL

0.39mL

19.74mL

3.95mL

1.97mL

39.49mL

7.90mL

3.95mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories